FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Aviva C. Krauss(Center for Drug Evaluation and Research), Xin Gao(Center for Drug Evaluation and Research), Liang Li(Center for Drug Evaluation and Research), Michael L. Manning(Center for Drug Evaluation and Research), Paresma Patel(Center for Drug Evaluation and Research), Wentao Fu(Center for Drug Evaluation and Research), Kumar G. Janoria(Center for Drug Evaluation and Research), Gerlie Gieser(Center for Drug Evaluation and Research), David A. Bateman(Center for Drug Evaluation and Research), Donna Przepiorka(Center for Drug Evaluation and Research), Yuan Li Shen(Center for Drug Evaluation and Research), Stacy S. Shord(Center for Drug Evaluation and Research), Christopher M. Sheth(Center for Drug Evaluation and Research), Anamitro Banerjee(Center for Drug Evaluation and Research), Jiang Liu(Center for Drug Evaluation and Research), Kirsten B. Goldberg(Center for Drug Evaluation and Research), Ann T. Farrell(Center for Drug Evaluation and Research), Gideon M. Blumenthal(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration)
Clinical Cancer Research
December 12, 2018
Cited by 324Open Access
Full Text

Abstract

Abstract On August 3, 2017, the FDA granted regular approval to Vyxeos (also known as CPX-351; Jazz Pharmaceuticals), a liposomal formulation of daunorubicin and cytarabine in a fixed combination, for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC). Approval was based on data from Study CLTR0310-301, a randomized, multicenter, open-label, active-controlled trial comparing Vyxeos with a standard combination of daunorubicin and cytarabine (“7+3”) in 309 patients 60–75 years of age with newly diagnosed t-AML or AML-MRC. Because of elemental copper concerns with the Vyxeos formulation, patients with Wilson disease were excluded from the study. Vyxeos demonstrated an improvement in overall survival (HR 0.69; 95% confidence interval, 0.52–0.90; P = 0.005) with an estimated median overall survival of 9.6 months compared with 5.9 months for the “7+3” control arm. The toxicity profile of Vyxeos was similar to that seen with standard “7+3” with the exception of more prolonged neutropenia and thrombocytopenia on the Vyxeos arm. Because the pharmacology of Vyxeos differs from that of other formulations of daunorubicin and cytarabine, labeling includes a warning against interchanging formulations during treatment. This is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC.


Related Papers

No related papers found

Powered by citation graph analysis